← Eichor
Study identifier: NCT07140367 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

"Transarterial Microembolization (TAME) in Inflammatory Knee Pathology"

Condition: Inflammatory Articular Diseases · Knee Osteoarthristis  ·  Sponsor: Istituto Ortopedico Rizzoli

PhaseN/A
Planned participants43
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

Patients with knee OA and chronic pain refractory to at least 3 months of conventional conservative therapy will be included in the study, which will evaluate the clinical results obtained after treatment with selective arterial embolization (selection and enrollment, treatment with selective arterial embolization, follow-up checks). Forty-three patients will be included in the study and will undergo the transarterial microembolization procedure after signing the informed consent form for participation in the study and the collection of anamnestic data. Subsequently, patients will be followed up with clinical evaluation at 1, 3, 6, 12, and 24 months of follow-up or until possible dropout for other treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Giancarlo Facchini, Medicine and Surgery  ·  +39 0516366836  ·  giancarlo.facchini@ior.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS Istituto Ortopedico RizzoliBologna, Bologna, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07140367